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Abstract
AIM: To analyze the incidence and possible risk 
factors in hospitalized patients treated with Clostridium 
difficile  infection (CDI).
METHODS: A total of 11751 patients were admitted 
to our clinic between 1 January 2010 and 1 May 
2013. Two hundred and forty-seven inpatients were 
prospectively diagnosed with CDI. For the risk analysis 
a 1:3 matching was used. Data of 732 patients 
matched for age, sex, and inpatient care period and 
unit were compared to those of the CDI population. 
Inpatient records were collected from an electronic 
hospital database and comprehensively reviewed. 
RESULTS: Incidence of CDI was 21.0/1000 admissions 
(2.1% of all-cause hospitalizations and 4.45% of 
total inpatient days). The incidence of severe CDI 
was 12.6% (2.63/1000 of all-cause hospitalizations). 
Distribution of CDI cases was different according to the 
unit type, with highest incidence rates in hematology, 
gastroenterology and nephrology units (32.9, 25 and 
24.6/1000 admissions, respectively) and lowest rates 
in 1.4% (33/2312) in endocrinology and general 
internal medicine (14.2 and 16.9/1000 admissions) 
units. Recurrence of CDI was 11.3% within 12 wk 
after discharge. Duration of hospital stay was longer in 
patients with CDI compared to controls (17.6 ± 10.8 
d vs  12.4 ± 7.71 d). CDI accounted for 6.3% of all-
inpatient deaths, and 30-d mortality rate was 21.9% 
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burden[4-6].
Previously increasing incidence was only reported 
in long-term care facilities. In contrast, recent studies 
report both community onset CDI[7] and acute hospital 
care onset[8]. Annual incidence of Clostridium difficile 
associated diarrhea and colitis (CDAD and CDAC, 
respectively) sharply increased from 35 to 156/100000 
in past twenty years in Quebec[9]. The increase was 
more significant in elderly patients, 65 years and 
above, (number of CDI reports furthermore elevated 
via mandatory surveillance healthcare systems)[10].
Not only did the incidence, but also the number of 
complicated cases and mortality rates increased[11]. 
Of note, asymptomatic carriers and colonization of 
colon microbial flora is observed in about 3% of the 
population, although in a much higher proportion 
of patients after long hospital stays and surgery[12]. 
The spectrum of clinical manifestations associated to 
Clostridium difficile can diverge from asymptomatic 
carriers to life-threatening infection. CDI symptoms can 
vary between diarrhea and colitis or enteritisto even life-
threatening complicated forms, pseudomembranosus, 
fulminant colitis or toxic megacolon. Some studies 
reported decreasing incidence of severe CDI. Feuerstadt 
et al[12] reported improved prognosis and decreased 
mortality (30-d mortality decreased significantly in 
both the overall (17.1% vs 13.1%, P < 0.01) and in 
the severe CDI (31.3% vs 23.3%, P < 0.05) cohorts 
between CDI 2006-2008 and 2009-2011.
Recently reported epidemic and wide-spreading of 
Clostiridum difficile infections are associated with health 
care associated factors and resistant strains (e.g., 
NAP1/B027)[13]. Suggested risk factors for developing 
CDI include prior antibiotic use, acid suppressive 
agents[14,15], previous CDI[16], comorbidities, malignancies, 
gastrointestinal disorders[17] and inflammatory bowel 
diseases[18].
Since there are only limited retrospective data are 
available from Eastern Europe, our aim was to analyze 
prospectively the incidence, possible risk factors, 
treatment strategy and outcome of CDI infections in 
hospitalized patients, treated at the 1st Department of 
Medicine, Semmelweis University, Budapest, Hungary.
MATERIALS AND METHODS
Patients
All patients admitted to the 1st Department of Medicine, 
Semmelweis University, Budapest, Hungary between 1 
January 2010 and 1 May 2013 prospectively evaluated. 
Our institution is an academic center with a secondary 
referral center including all specialities of internal 
medicine and oncology and provides primary internal 
medical care for a region of about 225000 inhabitants 
with a secondary referral area of 750000 to 1500000 
inhabitants for specialized care. A total of 11751 
inpatients were admitted in our clinic during the follow-
up period, including all cause of hospital admission. 
Total 601 stool sample tested for CDI in Microbiology 
Department of Semmelweis University, microbiological 
(54/247 cases). Risk factors for CDI were antibiotic 
therapy [including third-generation cephalosporins or 
fluoroquinolones, odds ratio (OR) = 4.559; P  < 0.001], 
use of proton pump inhibitors (OR = 2.082, P  < 0.001), 
previous hospitalization within 12 mo (OR = 3.167, 
P  < 0.001), previous CDI (OR = 15.32; P  < 0.001), 
while presence of diabetes mellitus was associated 
with a decreased risk for CDI (OR = 0.484; P  < 0.001). 
Treatment of recurrent cases was significantly different 
from primary infections with more frequent use of 
vancomycin alone or in combination (P  < 0.001), and 
antibiotic therapy duration was longer (P  < 0.02). 
Severity, mortality and outcome of primary infections 
and relapsing cases did not significantly differ.
CONCLUSION: CDI was accounted for significant 
burden with longer hospitalization and adverse outcomes. 
Antibiotic, PPI therapy and previous hospitalization or 
CDI were risk factors for CDI.
Key words: Clostridium difficile  infection; Hospitalization; 
Antibiotics; Proton pump inhibitors
© The Author(s) 2015. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Clostridium difficile  infection (CDI) is one of 
the most common healthcare-associated infections. 
It has a high economic burden and its incidence is 
rapidly increasing in long-term care facilities and acute 
care hospitals. In the present study, we reported an 
epidemic of CDI with one of the highest incidences 
to date. Previous antibiotic treatment, proton pump 
inhibitor use, previous hospitalization, higher Charlson 
Comorbidity Index, and previous CDI were identified 
as predictive factors. CDI was associated with a 
high healthcare burden, long hospital stay and high 
mortality.
Kurti Z, Lovasz BD, Mandel MD, Csima Z, Golovics PA, Csako 
BD, Mohas A, Gönczi L, Gecse KB, Kiss LS, Szathmari M, 
Lakatos PL. Burden of Clostridium difficile infection between 
2010 and 2013: Trends and outcomes from an academic center in 
Eastern Europe. World J Gastroenterol 2015; 21(21): 6728-6735 
Available from: URL: http://www.wjgnet.com/1007-9327/full/
v21/i21/6728.htm  DOI: http://dx.doi.org/10.3748/wjg.v21.
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INTRODUCTION
Clostridium difficile infection (CDI) is one of the 
most common antibiotic-associated complications 
nowadays and a leading cause of healthcare associated 
infections[1]. The incidence of CDI is dramatically 
increasing since 2000[2] and its rising severity is 
well represented by more frequent transfer to the 
intensive care unit, colectomy and infection associated 
mortality[3]. It results in remarkable healthcare system 
costs and eventually leads to an important healthcare 
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serology test, including 168 positive and 433 negative 
result and including recidive cases. Testing density was 
5.11/10000 patient-days.
A total of 247 inpatients had a confirmed diagnosis 
of CDI based on the clinical symptoms, laboratory 
results and cytotoxin stool testing and/or stool culture. 
Patient data were collected from the hospital electronic 
database.
Methods
CDI was defined as an acute diarrheal disease (more 
than three liquid stools per day) with a positive 
cytotoxin stool assay or a positive cytotoxin stool assay 
associated with the diagnosis of pseudomembranous 
colitis by imaging or endoscopic methods, surgery, 
or autopsy[19]. Repeated exotoxin positivity in 3 mo 
were defined as recurrence. In our department we 
apply standardized medical protocols and surveillance 
guidelines for healthcare associated infections (HAI) 
including CDI, and thus evaluation of symptomatic 
patients and treatment strategy is harmonized.
For defining the possible risk factors a 1:3 matching 
was used. Data of 732 inpatients matched for age, 
gender, inpatient care period and unit were compared to 
the CDI population. Inpatient records were collected and 
comprehensively reviewed, including inpatient ward, 
co-morbidities (according to Charlson Comorbitiy Index 
and age-adjusted Charlson Comorbidity Index[20]), 
medication use (including previous or current antibiotic 
treatment, proton pump inhibitors and any medication 
for the treatment of co-morbidities and the current CDI 
episode), laboratory parameters [white blood cell count 
(WBC), creatinine, C-reactive protein (CRP), serum 
albumin level].
Severe CDI was defined as WBC 15 G/L or above 
and serum albumin level 30 g/L or below based on 
previous guidelines[21].
Community acquired CDI defined as symptoms 
developed before hospital admission or less than 48 h 
after[22].
Three different outcomes were uses, such as 
recovered, recurrence after healing (within 12 wk), 
and death. Recurrence was defined as a clinical relapse 
including symptoms and positive stool test within 12 
wk from the discharge.
Ethical permission
The study protocol was approved by the Semmelweis 
University Regional and Institutional Committee of 
Science and Research Ethics (TUKEB 56/2013).
Statistical analysis
SPSS version 20 (SPSS Inc., Chicago, IL, United 
States) was used for statistical analysis. D-test, 
ANOVA-Scheffe test were used to compare continuous 
variables, Khi2, Fischer-exact tests were used to 
compare categorical variables. Categorical variables 
if appropriate were further tested in a multivariate 
analysis by using logistic regression analysis. Variables 
with a P vaule < 0.1 were included in the multivariate 
testing. Kaplan-Meier curve was plotted to analyse 
mortality outcomes with LogRank test. A P value of < 
0.05 was considered significant.
RESULTS
Incidence of CDI and severe CDI
The crude incidence of CDI infection was 21.0 per 
1000 all-cause hospital admissions (2.1% of all-cause 
hospitalizations), 4.45% of total inpatient days were 
related to CDI (4326/96284 d, equaling 25.6 cases per 
10000 patient-days) during the observed period. The 
majority of the patients were 60 years or older (< 40 
years old: 4.7%, 40-60 years old: 11.9%, > 60 years 
old: 83.4%). Community acquired infection rate was 
45.3%. Symptoms were detected at hospitalization in 
82 patients (33.2%) and within 3 d from admission in 
further 30 patients (12.1%). Mean time to presence 
of CDI symptoms was 2.75 ± 5.3 d from hospital 
admission.
Total 601 stool sample tested for Clostridium difficile 
infection in Microbiology Department of Semmelweis 
University, microbiological serology test, including 168 
positive and 433 negative result and including relapses. 
Testing density was 5.11/10000 patient-days.
The incidence of CDI was different according to the 
unit type, with highest incidence rates in hematology, 
gastroenterology and nephrology units (32.9, 25 and 
24.6/1000 admissions) and lowest rates in 1.4% 
(33/2312) in endocrinology and general internal medicine 
(14.2 and 16.9/1000 admissions) units. Incidence did 
not differ between genders.
The incidence of severe CDI was 12.6% (2.63/1000 
of all cause hospitalizations). In severe CDI patients were 
older (severe: 84.2% vs all: 69.6% of patients were 
> 65 years, P < 0.001) and duration of hospitalization 
was longer (18.4 ± 11.7 inpatient days vs 17.3 ± 10.3 
inpatient days, P < 0.001).
Risk factors for CDI
Serum creatinine level, WBC and CRP were higher 
while serum albumin level was lower in patients with 
CDI compared to controls. Charlson Comorbity Index 
and age-adjusted Charlson Comorbidity Index were 
also significantly higher in CDI cases compared to 
controls (5.6 ± 3.1 and 6.8 ± 2.7 vs 4.8 ± 3.0 and 5.9 
± 2.7, P < 0.001). More detailed description of clinical 
and laboratory parameters are shown in Table 1.
Risk factors for CDI included previous “risk” 
antibiotic therapy (clindamycin, penicillins, third 
generation cephalosporins and fluoroquinolones, P < 
0.001), use of proton pump inhibitors (OR = 2.08, P 
< 0.001), previous hospitalization within 12 mo (OR = 
3.16, P < 0.001), previous CDI (OR = 15.3, P < 0.001). 
The presence of diabetes mellitus was associated with a 
decreased risk for CDI (OR = 0.48, P < 0.001) (Table 2).
Kurti Z et al . Clostridium difficile  infection
Table 2  Risk factors for Clostridium difficile  infection in 
inpatients
Table 1  Clinical and laboratory parameters of patients with 
Clostridium difficile  infection and controls
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Treatment strategy
Treatment of primary infection was started with 
metronidazole in 70.8% of the patients (28.4% iv and 
42.4% oral), vancomycin alone in 7.7% or combination 
therapy in 21.5%. Change in the antibiotic treatment 
was required in 11.9%. The mean length of antibiotic 
treatment was 12.1 ± 6.9 d. The initial treatment of 
severe CDI included combination therapy in 31.6%, 
metronidazole in 60.5% or vancomycin alone in 7.9% 
of the cases. Change in the antibiotic therapy was 
required in 15.8% of the patients. The length of the 
treatment was 13.6 ± 5.9 d, and 12.6 ± 7.1 d in 
severe cases.
Treatment strategy was different in community vs 
hospital-acquired cases with a tendency towards higher 
metronidazole (P = 0.07) and lower vancomycin (P = 
0.004) and/or combination therapy (P = 0.04) rates in 
the community acquired cases. A similar proportion of 
the patients required a change of the first therapy.
The treatment strategy was not significantly 
different according to the unit type, age or gender (data 
not shown).
Treatment of recurrent cases was significantly 
different from primary infections (86.7% vancomycin 
based including 53.3% combination vancomycin-
metronidazole vs 29.2% vancomycin-based therapy 
in primary CDI, P < 0.001). Length of treatment 
recurrent infections was 16.6 days, longer compared 
to the primary cases (P = 0.03 vs primary CDI).
Outcome of CDI infection
Duration of hospital stay was longer (17.6 ± 10.8 d vs 
12.4 ± 7.7 d, P < 0.01) in patients with CDI infection 
compared to the controls. Length of hospitalization was 
not different between age-groups (data not shown); 
8.1% of the patients required ICU therapy during the 
CDI infection.
The 30-d mortality rate was 21.9% in CDI patients 
(54/247 cases), equaling 6.3% of all-inpatient deaths 
(37/555) (Figure 1). In addition, mortality rates were 
different according to age with highest mortality in the 
eldest patients (21.7% in > 60 years old, 16.7% in 
40-60 years old and 0% in younger patients, P = 0.053, 
Figure 2).
Recurrence of CDI infection was 11.3% (n = 26) 
12 wk after discharge. The outcome of recurrent cases 
was not significantly different from that of the primary 
infection. The rate of severe CDI was 5.9% and 30-d 
mortality was 23.8% (Figure 1).
CDI cases Controls P  value
(n  = 247) (n  = 732)
Age (yr)   72.4 (14.2)   70.6 (13.8) NS
Male/female 90/157 276/455 NS
Charlson Index   5.6 (3.1)   4.8 (3.0) < 0.001
Age-adjusted Charlson 
Comorbidity Index
  6.8 (2.7)   5.9 (2.7) < 0.001
CRP (mg/L)   108.3 (101.3)   49.8 (74.0) < 0.001
Procalcitonin (mg/L)   1.8 (8.1)     1.2 (12.4) NS
WBC count (G/L)   14.3 (20.9)   9.9 (8.4) < 0.001
Albumin (g/L) 29.5 (9.9)   36.2 (11.2) < 0.001
Creatinine (μmol/l)   158.3 (158.2)   124.1 (117.7) < 0.001
Na (mmol/L) 137.7 (14.7) 136.1 (25.1) NS
K (mmol/L)   4.1 (4.4)   4.4 (4.8) NS
Data are expressed as mean ± SD. CDI: Clostridium difficile infection; CRP: 
C reactive protein; NS: Not significant; WBC: White blood cell count.
Univariate analysis Multivariate analysis
Gender P = 0.77 P = 0.47
Previous Clostridium 
difficile infection
P < 0.001, P = 0.08
OR = 15.3
95%CI: 2.03-48.7
Previous 
hospitalization1
P < 0.001, P < 0.001,
OR = 3.17 OR = 2.39,
95%CI: 2.19-4.57 95%CI: 1.61-3.51
Healthcare facility or 
nursery home
P = 0.06 P = 0.81
Treatment with "risk" 
antibiotics
P < 0.001 , P < 0.001
OR = 4.56 OR = 4.09,
95%CI: 3.36-6.19 95%CI: 2.98-5.61
Proton pump inhibitor 
therapy
P < 0.001, P = 0.006
OR = 2.08 OR = 1.62,
95%CI: 1.52-2.85 95%CI: 1.15-2.29
Charlson Comorbidity 
Index
P = 0.001 P = 0.004
OR = 1.08,
95%CI: 1.03-1.14
1Within 1 year from index hospitalization. Previous “risk” antibiotic 
therapy: clindamycin, penicillins, third-generation cephalosporins, or 
fluoroquinolones. Previous treatment strategy was registered within 1 year 
from diagnosis of CDI. Proton pump inhibitor therapy was defined as at 
least the suggested daily dose (20 mg omeprazole, 30 mg lansoprazole, or 
40 mg pantoprazole or esomeprezol). OR: Odds ratio; NA: Not applicable. 
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Figure 1  Early mortality of patients with Clostridium difficile infection. 
Primary infection vs relapse, within 30 d from admission. P log rank = 0.64. C. 
Difficile: Clostridium difficile; CDI: Clostridium difficile infection.
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DISCUSSION
This is the first prospective systematic evaluation of 
the incidence, risk factors, treatment and outcomes of 
CDI in a tertiary academic center in Eastern Europe in 
inpatients. CDI was associated with a high health care 
burden and it was responsible for 4.5% of inpatients 
stays, leading to long hospital stay and high mortality 
(21.9%). The incidence of severe CDI was 12.6% 
while recurrence of CDI infection was 11.3% within 
12 wk after discharge. Primary CDI infection was 
initially treated by metronidazole-based regimen, while 
severe or recurrent cases were significantly more 
often treated initially with vancomycin, alone or in 
combination.
Previous studies reported increasing incidence 
rates from Western Europe and North America. The 
mean prevalence of CDI increased from 261 to 546 
discharged cases per 100000 patients in a nationwide 
study from the United States between 1993 and 
2003[23] (Estimations were based on the discharge 
data from the Nationwide Inpatient Sample. Similar 
results were published from another multicenter study 
between 2000 and 2006. The incidence of hospital-
onset CDI increased from 7 to 8.5 cases/10000 
patient-days, similarly the community-onset CDI 
increased from 1.1 to 1.3 cases/10000 patient-days[24]. 
A striking rise in incidence was reported from the 
Quebec region: 35.6 per 100000 population in 1991 to 
156.3 per 100000 in 2003, with some local geographic 
variation. Of note, the highest increase was observed 
among patients aged 65 years or above (from 102.0 
to 866.5 per 100000)[9].
In concordance, the incidence rate of CDI was 
21/1000 all cause hospital admission and the majority 
(83.4%) of patients were elderly (older than 60 years). 
Importantly, the diagnosis of CDI in the present study 
was based on clinical symptoms and positive cytotoxin 
assay. A systematic stool evaluation by patients with 
non-suggestive clinical symptoms was not performed. 
Therefore, a proportion of mild cases may have been 
unnoticed.
In a multinational European study, the mean 
incidence of CDI was 4.1 per 10000 patient-days, 
with 63% of the patients aged 65 years or more as 
extrapolated from the results obtained in November 
2008, from single hospitals[25]. Of note, a significant 
geographic variation was reported with the highest 
rate in Finland (19.1 per 10000 patient-days) and the 
lowest in Turkey and Bulgaria (0 and 0.6 per 10000 
patient-days). Interestingly, very low incidences were 
reported from Eastern European countries including 
Bulgaria, Croatia, Czech Republic, Romania, Slovakia 
and Hungary (2 per 10000 patient-days). In contrast, 
Poland reported one of the highest incidences (12.5 
per 10000 patient-days). The incidence in the present 
study equals 25.6 cases per 10000 patient-days, which 
is one of the highest reported in Europe, 5 to 10-fold 
higher compared to the Eastern European data in the 
multicenter study from 2008.
Few other data are available from Eastern Europe. 
Surprisingly low, 0.6 per 10000 patient-days incidence 
rate was reported from a university center from Croatia 
by Novak et al[26] in 2010. Similarly low incidence was 
reported in a Czech tertiary referral center by Balihar et 
al[27] in 2014, with an incidence of 0.6 per 10000 and 
15.8% severe cases, in a retrospective observational 
study[27]. Finally, the incidence rate in the present study 
was almost 5-times higher than in the recently published 
data from Austria (5.23 per 10000 patient-days)[28]. 
The rate of severe CDI was similar in the present study 
(12.6%) to that reported from Austria (16.5%). Patients 
with severe CDI were older and CDI was associated with 
longer hospital stay. Interestingly, even higher severe 
CDI rates were reported from the US (20.1%) between 
2006 and 2011[12] and from Canada (rising from 7.1% in 
1991-1993 to 18.2% in 2003)[9].
Previous antibiotic treatment (clindamycin, amocillin/
clavulanic acid, cephalosporins, ciprofloxacin and flu-
oroquinolones), acid suppressive agents, previous 
hospitalizations, long-term care home residence and 
comorbidities were previously reported as risk factors 
for CDI[14-16,29-31]. In concordance, in the present 
study previous antibiotic treatment with the above 
compounds, proton pump inhibitor use, previous 
hospitalization, higher Charlson Comorbidity Index, 
and previous CDI were identified as predictive factors 
for CDI. In addition, higher creatinine, lower serum 
albumin level and higher white blood cell count was 
associated with CDI and in previous studies with 
adverse outcomes[9]. Male gender, elevated CRP and 
fluoroquinolone exposure was associated with severe 
CDI and more frequent transition to intensive care 
unit[32]. The protective association found for diabetes 
mellitus might represent a selection bias, since the 
chance for being hospitalized with any gastrointestinal 
symptoms, especially diarrhea (as well as the CDI 
incidence) was lower in the endocrinology unit com-
pared to the gastroenterology, nephrology or hema-
tology units.
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Previous studies suggested a benefit from 
vancomycin-based treatment strategy, especially in 
patients with severe CDI preventing adverse outcomes 
and the development of complicated CDI[9]. In a 
recent paper from the US, authors reported a shift 
in the treatment patterns, with shorter duration of 
oral metronidazole (P < 0.001), longer duration of 
intravenous metronidazole (P = 0.04), more frequent 
use of vancomycin (P < 0.001) and more frequent 
switching from metronidazole to vancomycin (P < 0.001) 
between 2006 and 2011[12]. In the present study, 
patients received a tailored therapy with increased 
and earlier use of vancomycin in severe and recurrent 
cases. Largely similarly treatment data were presented 
from the Czech Republic[27]. Interestingly, in the present 
study, treatment strategy was different in community 
vs hospital-acquired cases, with higher metronidazole 
and lower vancomycin/combination rates in community 
acquired cases.
Readmission rate (11.3%) in the present study was 
lower compared to that reported from North America 
(16%-18%)[12,33] and the Czech Republic (16.4%). 
However, even lower readmission rates were reported 
in a multicenter study from Canada (7%)[34]. The 
average total length of hospital stay in the present 
study was in the range of previous findings with a 
mean incremental length of stay of 5.0-13.6 and 
2.7-21.3 d for CDI requiring admission and hospital 
acquired CDI episodes[35]. Of note, much longer mean 
hospital stay was reported recently from the Czech 
Republic (median 35 d)[27].
Despite the relatively aggressive treatment str-
ategy, the 30-d mortality rate in the present study was 
as high as 21.9%. The higher Charlson Comorbidity 
Index and overall high proportion of elderly patients 
may at least partly explain this finding. Similar 
mortality rates were reported recently from the Czech 
Republic (overall: 19.7%, hospital-acquired: 22.4% 
and in severe-CDI: 62%) in a cohort with similar age 
distribution and comorbidity pattern. A mortality rate 
of 15.2% was reported in a multicenter study from 
Canada[35]. In another Canadian study death rate in 
complicated and non-complicated CDI was between 
19%-25.5% and 4.2%-11.3% without a clear 
time trend between 1991 and 2003[9]. In addition, 
increasing adjusted mortality rates were reported in 
the US in the Nationwide Inpatient Sample between 
1993 and 2003. Mortality rates increased from 20.3 
deaths per 100000 discharges in 1993 to 50.2 deaths 
per 100000 discharges in 2003[23]. In contrast, lower 
and improving mortality rates were reported more 
recently from the US (overall: 17.1% vs 13.1%, P < 
0.01 and severe CDI: 31.3% vs 23.3%, P < 0.05) 
between 2006 and 2011, despite a higher Charlson 
Comorbidity Scores and older population in the more 
recent cohort[12]. Finally, mortality rate (11.0%) was 
lower in a case-control study from Japan, while risk 
factors for CDI were not different from Europe and 
North America[36]. Of note, in the latter study only 
the use of vancomycin but not metronidazole was 
associated with a decreased risk for mortality.
Authors are aware of potential limitations of this 
study including the possible underestimation of the 
incidence due to the strict inclusion criteria. Cases 
were identified by suggestive symptoms and cytotoxin 
test positivity, therefore milder cases might have 
remained unidentified. Demographic data was only 
partly registered, e.g., nursery home care was not 
always documented. Conventional treatment methods 
were used in our university hospital for CDI, including 
vancomycin and/or metronidazole therapy and patient 
isolation. The use of new antibiotics, e.g., fidaxomicin, 
tigecyclin or fecal microbiota transplantation was 
exceptional with only one patient evaluated for fecal 
microbiota transplantation. In the present study, 
definition of severe CDI was based on Society for 
Healthcare Epidemiology of America (SHEA) guidelines, 
but this severity based evaluation was not validated 
previously. In contrast, the strengths of the present 
study include the prospective, complete capture. 
Cases were identified through the full electronic online 
in- and outpatient medical records, which is linked 
to the microbiology and laboratory data, making 
the search, data capture and analysis extremely 
reliable. The system contains all out- and inpatient 
records related to the patient including laboratory 
data, imaging, hospitalization and/or surgery related 
hospitalization records from all departments of the 
Semmelweis University since 2005. In addition, we 
apply standardized medical protocols and surveillance 
guidelines in our Department for HAI including CDI, 
and thus evaluation of symptomatic patients and 
treatment strategy is harmonized in the different units 
of the department.
In conclusion, the incidence of CDI was high in 
this prospective study, and was associated with longer 
hospital stay and adverse outcomes. Early readmission 
rates were comparable to findings of previous studies. 
A relatively high proportion of patients received 
aggressive antibiotic therapy and this was tailored to 
the severity of the cases. Antibiotic therapy, proton 
pump inhibitor treatment, previous hospitalization and 
CDI were identified as risk factors for CDI.
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